Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » BioLegend Licenses Single-Cell Analysis Technology from New York Genome Center

BioLegend Licenses Single-Cell Analysis Technology from New York Genome Center

Jan 11, 2018
|
staff reporter

NEW YORK (GenomeWeb) – BioLegend has licensed a multidimensional single-cell analysis technology from the New York Genome Center and is collaborating with the center on further research, the two organizations said today.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Shift to New Variant Work

Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.

Victim Identified with Genetic Genealogy

According to the Associated Press, genetic genealogy has helped law enforcement officials identify an unknown victim of the Green River Killer.

PNAS Papers on Chemotherapy-Induced Cardiac Injury Target, Viral Insertions, SMRT Methylation Profiling

In PNAS this week: target to reduce chemotherapy-induced cardiac injury, tool finds ancient endogenous RNA viruses, and more.

Should Also Work

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.

What's Popular?

In Business News

  1. Thermo Fisher Scientific, SPT Labtech to Comarket Sequencing Library Prep Products

  2. Illumina Wins UK Patent Infringement Suit Against BGI, Affiliates

  3. Ancestry Shutters Health Offering, Raising Questions About Future of Consumer Genomics

    Premium

  4. Split Biosciences Rebrands as Parse Biosciences, Raises $7M in Series A Financing

  5. Ambry Genetics Gets FDA Emergency Use Authorization for Coronavirus Test

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.